Date published: 2025-10-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

ZYG11A Inhibitors

ZYG11A Inhibitors consists of compounds that indirectly influence the activity of ZYG11A, a protein implicated in cell cycle regulation and connected to the ubiquitin-proteasome system. These inhibitors do not directly target ZYG11A. Instead, their impact is mediated through the disruption of cellular pathways and processes crucial for ZYG11A's function. Predominantly, this class includes agents that affect the ubiquitin-proteasome pathway, a key system for protein degradation, and other related mechanisms involved in cell cycle control. By altering these pathways, the inhibitors can indirectly modulate the function of ZYG11A, particularly its role in targeting cell cycle regulators for degradation. The primary mode of action for these inhibitors involves the obstruction of proteasomal degradation, which is integral to the degradation of proteins marked by ZYG11A for ubiquitination. This blockage leads to an accumulation of proteins that ZYG11A typically targets, thus impacting cell cycle progression. By preventing the normal degradation of these regulatory proteins, the inhibitors indirectly influence ZYG11A's function in maintaining cellular homeostasis and regulating the cell cycle. Additionally, compounds that modulate the ubiquitination process can disrupt the tagging of proteins, leading to changes in the turnover and stability of cell cycle regulators. This, in turn, affects the regulatory role of ZYG11A. The use of these inhibitors highlights the complex interplay between cellular processes and the regulation of critical proteins like ZYG11A. By influencing key pathways such as protein degradation and ubiquitin tagging, these compounds provide a means to indirectly modulate the activity of ZYG11A. This indirect approach underscores the intricacies of targeting proteins involved in essential cellular functions and emphasizes the importance of a nuanced understanding of cellular mechanisms. The diversity in the mechanisms of action of these inhibitors reflects the multifaceted nature of cellular regulation and demonstrates the potential of these compounds to offer insights into the regulation of proteins like ZYG11A within the broader context of cellular function.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

MG132 is a proteasome inhibitor that could disrupt protein degradation pathways regulated by ZYG11A, affecting its functional role in cell cycle control.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib inhibits proteasome activity, potentially impacting the degradation of substrates targeted by ZYG11A in the cell cycle regulation process.

Lactacystin

133343-34-7sc-3575
sc-3575A
200 µg
1 mg
$165.00
$575.00
60
(2)

Lactacystin, as a proteasome inhibitor, may alter the turnover of proteins regulated by ZYG11A, affecting cell cycle progression.

Ixazomib

1072833-77-2sc-489103
sc-489103A
10 mg
50 mg
$311.00
$719.00
(0)

Ixazomib, by inhibiting the proteasome, could impact the degradation of cell cycle regulators targeted by ZYG11A.

Oprozomib

935888-69-0sc-477447
2.5 mg
$280.00
(0)

Oprozomib inhibits proteasome activity, potentially affecting the function of ZYG11A in the ubiquitin-proteasome pathway.

Oligomycin A

579-13-5sc-201551
sc-201551A
sc-201551B
sc-201551C
sc-201551D
5 mg
25 mg
100 mg
500 mg
1 g
$175.00
$600.00
$1179.00
$5100.00
$9180.00
26
(1)

Oligomycin A inhibits mitochondrial ATP synthase, potentially affecting cellular energy status and indirectly influencing ZYG11A's role in the cell cycle.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$40.00
$82.00
$256.00
127
(5)

Cycloheximide inhibits protein synthesis, potentially affecting the production and turnover of proteins like ZYG11A in the cell cycle regulation process.